ImmuCell Corporation (ICCC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ImmuCell Corporation (ICCC) is up 59.2% since the beginning of the year. At $10 per share, ICCC is trading 8.9% below its 52-week high of $11. Investors who bought $1,000 worth of ICCC shares 5 years ago would now be looking at an investment worth $1,028.

ImmuCell Corporation (ICCC) has returned 59.19% so far this year and 42.50% over the past 12 months. Over the last ten years, ICCC has returned 3.67% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Jul 10, 1995, ICCC's average daily return is +0.14%, while the average monthly return is +1.51%. At this rate, an investment would double in approximately 3.9 years.

Historically, 49% of months were positive and 51% were negative. The best month was Mar 1996 with a return of +80.0%, while the worst month was Mar 2020 at -34.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ICCC closed higher 41% of trading days. The best single day was Feb 8, 2000 with a return of +127.3%, while the worst single day was Feb 9, 2000 at -28.5%.

ImmuCell Corporation has an annualized alpha of 35.84%, beta of 0.37, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 11, 1995.

• This stock participated in 55.73% of S&P 500 Index downside but only 48.74% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.37 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ICCC ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for ImmuCell Corporation (ICCC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ImmuCell Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ImmuCell Corporation was 85.30%, occurring on Feb 27, 2009. Recovery took 1615 trading sessions.

The current ImmuCell Corporation drawdown is 17.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ImmuCell Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ImmuCell Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.